Co-Diagnostics Sales Plunge 93 Percent
Co-Diagnostics (NASDAQ:CODX), a diagnostics technology company focused on infectious disease testing, announced its Q2 2025 results on August 14, 2025. GAAP EPS loss of $0.23 was better than analysts' estimate of a $0.25 loss. However, GAAP revenue fell short at $0.2 million, compared to the $0.3 million analysts anticipated, and marking a sharp drop from $2.7 million in Q2 2024. While the loss shrank, revenue relied heavily on grant timing, accentuating the company’s ongoing pre-commercial phase. The quarter reflected both progress in product development and the financial pressures of a business not yet generating steady sales.
Source: Analyst estimates for the quarter provided by FactSet.
Co-Diagnostics specializes in molecular diagnostics, with a focus on infectious disease detection using polymerase chain reaction (PCR) technology. At its core is the proprietary Co-Primers technology, which is designed to enhance the accuracy and specificity of PCR tests by reducing common errors like false positives caused by primer-dimers. Its business centers on developing tests and platforms that can be used both at point-of-care settings and at home, aiming to offer affordable, accurate diagnostic solutions globally.
Source Fool.com
